ArticleEClinicalMedicine2024

Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial.

Alexander Zarbock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.